As of Feb 27
| -0.19 / -2.07%|
The 2 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 11.50, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +27.92% increase from the last price of 8.99.
The current consensus among 3 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.